How Cannabis Impacts Health & the Potential Risks | Dr. Matthew Hill

The episode is a detailed, debate-turned-collaboration about the biology of cannabis. Hill explains how THC acts on CB1 receptors and how the endocannabinoid system (anandamide and 2-AG) maintains homeostasis, then covers the munchies, memory effects, routes of administration (smoking vs. edibles vs. concentrates), tolerance, and cannabis use disorder. A long central section argues that the cannabis-schizophrenia link is likely correlation (shared biological vulnerability or self-medication) rather than causation. They also debunk the indica-vs-sativa distinction as expectancy bias, question the entire CBD wellness market as placebo at common doses, and close on genuine harms and the few evidence-backed medical uses (chronic pain, anxiety, PTSD nightmares, pediatric epilepsy).

• Hill states it appears physically impossible to fatally overdose on THC because CB1 receptors are absent from the brainstem regions that control heart and breathing (unlike opioids).
  00:33:24
• People and even rats self-titrate cannabis to roughly the same blood THC level (~100 ng/mL) regardless of flower potency — so high-THC flower isn't the real danger; concentrates (which double or triple that) are.
  01:11:48
• Among people who use cannabis weekly, roughly 30% may meet criteria for cannabis use disorder.
  01:26:13
• Hill argues cannabis likely does NOT cause schizophrenia de novo — Scandinavia has very low cannabis use but similar schizophrenia rates to high-use North America; genetics studies suggest schizophrenia risk predicts cannabis use more than the reverse.
  02:33:50
• Indica vs. sativa labels are botanical (plant shape) and do not track chemical composition; reported differences are expectancy bias — the biggest predictor of effect is what the label says it will do.
  02:47:46
• Hill claims the overwhelming majority of consumer CBD effects are placebo, because clinical doses are 300–2000 mg while gummies contain only 2–25 mg with ~4% bioavailability.
  03:10:27
• Cannabinoid hyperemesis syndrome — intractable vomiting in heavy users — is bizarrely relieved by a hot shower (and capsaicin cream or propranolol).
  03:27:17
• A small double-blind Canadian military trial found nabilone suppressed PTSD nightmares in ~85% of a treatment-resistant veteran population.
  03:37:36

• The first THC paper was reportedly published April 20, 1964 — a possible (unverified) origin of the '420' reference.
  00:28:09
• Anandamide is named after the Sanskrit word 'ananda' (bliss); its discoverer Raphael Mechoulam, who also first isolated THC, named it for inner bliss.
  00:27:05
• Dopamine neurons are essentially the only neurons in the brain that don't express cannabinoid receptors directly.
  00:23:58
• For decades, U.S. cannabis research legally had to use weak (~5–9% THC) cannabis grown at a single NIDA-funded farm in Mississippi.
  01:08:39
• Edibles cause most adverse cannabis events because onset takes 30–90 minutes, so people redose before the first dose hits.
  01:39:10
• THC is fat-soluble and stored in fat; exercise or weight loss can release it and make someone test positive again after testing negative.
  01:41:13
• CBD was popularized after Sanjay Gupta covered the Charlotte's Web strain on CNN around 2012; CBD has been largely bred out of street cannabis in favor of THC.
  03:01:11
• Cannabis doesn't strongly numb pain but strips away its affective component — patients say the pain becomes 'background noise' so they can sleep and function.
  03:32:59
• Cannabis has biphasic effects on anxiety: low doses reduce anxiety via CB1 on excitatory neurons, while high doses trigger panic by saturating CB1 on inhibitory neurons.
  02:10:28
• CBD has poor oral bioavailability (~4%), but eating a fatty meal can raise it to ~20%.
  03:13:09

Books, products and media the guest or host genuinely endorsed here — with the buy link.

Affiliate link — we may earn a commission at no extra cost to you.